Amgen Beats Earnings Expectations and Expands into Obesity Drug Space

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 32 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 47%
  • Publisher: 63%

Business Berita

Amgen,Earnings,Revenue

Amgen reported better-than-expected third-quarter earnings and raised its revenue guidance for the full year. The company recently acquired Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also venturing into the obesity drug market and has completed enrollment for a phase 2 trial for the treatment of obesity.

) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also looking to move into the obesity drug space which has garnered much attention from Wall Street.

Shakedown or smart business? Quebec restaurants balk at hefty penalty for using competitor's payment machines Warren Buffett's Japan trade felt like a gift from God, Charlie Munger says: 'It was awfully easy money' TSX energy stocks such as Suncor Energy should be part of your equity portfolio if you are bullish on oil prices in 2023. The post Oil Prices Are Rising: Here Are the Stocks That Will Benefit the Most appeared first on The Motley Fool Canada.Rated lowest margin fees by StockBrokers.com. Borrow against your securities at low cost. Rates subject to change. Your capital is at risk.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 47. in İD
 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics AcquisitionAmgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.
Sumber: SaltWire Network - 🏆 45. / 63 Baca lebih lajut »